{
  "pmcid": "2467497",
  "sha256": "0ee3daccd95a922b957fe1ccdd1b5b42d58d69083c445e8bdd5bf1bfb769fa52",
  "timestamp_utc": "2025-11-09T22:33:14.469306+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 15.221304347826088,
    "reading_ease": 13.243840579710167,
    "word_count": 230
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Isolated Hepatic Perfusion with Melphalan for Liver Metastases"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "This single-center trial included 19 patients"
      },
      "Participants": {
        "score": 2,
        "evidence": "Eligibility criteria included WHO performance status 0-1 and specific blood parameters."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Patients underwent a 60-min IHP with 200 mg melphalan."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study evaluates isolated hepatic perfusion (IHP) with melphalan in patients with isolated liver metastases from various primary tumors."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was tumor response according to RECIST criteria, measured over a median follow-up of 74 months."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Randomisation and blinding were not applicable as this was a single-arm study."
      },
      "Blinding": {
        "score": 0,
        "evidence": "Randomisation and blinding were not applicable as this was a single-arm study."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "This single-center trial included 19 patients"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Among the 18 patients analyzed"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "Median disease-free survival was 6.6 months, and median overall survival was 10.0 months."
      },
      "Harms": {
        "score": 1,
        "evidence": "reversible grade 3 or 4 hepatotoxicity occurred in 56%, and veno-occlusive disease in 22%."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "No trial registration or funding information was provided."
      },
      "Funding": {
        "score": 0,
        "evidence": "No trial registration or funding information was provided."
      }
    },
    "total_score": 14,
    "max_score": 25
  }
}